Chronic Inflammatory Skin Disease: Where We Are and Where We Are Going: 2nd Edition

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Dermatology".

Deadline for manuscript submissions: 31 March 2025 | Viewed by 650

Special Issue Editors


E-Mail Website
Guest Editor
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Napoli, Italy
Interests: hidradenitis suppurativa; psoriasis; atopic dermatitis; new treatment; skin inflammatory disease
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Napoly, Italy
Interests: inflammatory skin diseases; psoriasis; hidradenitis; atopic dermatitis; acne and rosacea; infective diseases; ontological diseases in dermatology (including melanoma and nonmelanoma skin cancers); teledermatology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Significant progress has been achieved in the last few decades in dermatology, especially regarding chronic inflammatory skin diseases. In recent years, great progress has also been made in understanding the pathogenesis of the most common inflammatory skin diseases such as psoriasis, atopic dermatitis, and hidradenitis suppurativa that has led to the development of selective and targeted innovative therapies. In particular, biological drugs (chimeric, humanized, and fully human monoclonal antibodies), biosimilars, and small molecules have completely revolutionized the treatment of chronic inflammatory skin diseases by opening new avenues for us clinicians. However, significant research efforts are still needed. New studies are needed to identify biomarkers for each disease, so that we clinicians may be able to diagnose and treat chronic inflammatory diseases early and predict responses to treatments so that we can choose the best treatment for each type of patient.

This Special Issue entitled “Chronic Inflammatory Skin Disease: Where We Are and Where We Are Going” is now open for submissions, welcoming papers that aim to bring together the most relevant scientific research on chronic inflammatory skin diseases, focusing on epidemiology, pathophysiology, and recent or emerging advances in therapy.

Dr. Fabrizio Martora
Dr. Matteo Megna
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • psoriasis
  • atopic dermatitis
  • hidradenitis suppurativa
  • skin inflammatory disease

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

9 pages, 630 KiB  
Review
Hidradenitis Suppurativa in Elderly Patients: Clinical and Therapeutical Outcomes—A Review of the Literature
by Fabrizio Martora, Nello Tommasino, Claudio Brescia, Luca Potestio, Teresa Battista and Matteo Megna
Medicina 2024, 60(9), 1465; https://doi.org/10.3390/medicina60091465 - 6 Sep 2024
Viewed by 530
Abstract
The management of hidradenitis suppurativa (HS) in elderly patients presents unique challenges due to its chronic inflammatory nature, heterogeneous clinical presentation and comorbidities. While HS typically affects the anogenital and intertriginous regions, elderly patients may exhibit atypical features such as the involvement of [...] Read more.
The management of hidradenitis suppurativa (HS) in elderly patients presents unique challenges due to its chronic inflammatory nature, heterogeneous clinical presentation and comorbidities. While HS typically affects the anogenital and intertriginous regions, elderly patients may exhibit atypical features such as the involvement of the neck, mammary area and gluteal region. The prevalence of HS in the elderly population is lower and the average age of disease onset is higher than in patients under 65. In contrast, it is unclear whether HS in the elderly has different clinical features. The elderly frequently present multiple comorbidities, including obesity, diabetes, and heart disease, which further complicate management decisions. Therapeutic interventions must consider the frailty and increased risk of multimorbidity and adverse events in elderly patients. While systemic antibiotics remain a mainstay of HS treatment, biologic agents such as TNFα inhibitors and secukinumab offer promising options for refractory cases. However, their safety and efficacy in elderly patients, particularly those with multiple comorbidities, require careful consideration. A comprehensive approach to managing HS in elderly patients involves not only pharmacological interventions but also lifestyle modifications and surgical options where appropriate. Multidisciplinary collaboration between dermatologists, geriatricians and other specialists is essential for tailoring treatment strategies and optimizing long-term outcomes and quality of life in special population. Full article
Show Figures

Figure 1

Back to TopTop